Twenty-five years of translational medicine in antiretroviral therapy: promises to keep.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20610849.
- Also identified by DOI 10.1126/scitranslmed.3000749.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The year 2010 marks the 25th anniversary of modern antiretroviral drug discovery and development. In the early 1980s, AIDS was almost always a lethal disease with an appalling clinical course characterized by severe opportunistic infections and unusual forms of cancer. Since that time, starting with zidovudine (AZT) and related 2',3'-dideoxynucleosides, the causative retrovirus, now called HIV-1, went from being an untreatable infectious agent to being the target of highly active antiretroviral therapy (HAART). This degree of progress refuted early prophesies of therapeutic futility and represents a striking example of translational medicine. Here I review foundational discoveries and events in HIV-1/AIDS research and explore lessons for future translational medicine efforts.
Medical subject headings
- Acquired Immunodeficiency Syndrome
- Antiretroviral Therapy, Highly Active
- Translational Research, Biomedical